Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 17, Number 2—February 2011
CME ACTIVITY - Synopsis

Hepatitis E Virus and Neurologic Disorders

Nassim KamarComments to Author , Richard P. Bendall, Jean Marie Peron, Pascal Cintas, Laurent Prudhomme, Jean Michel Mansuy, Lionel Rostaing, Frances Keane, Samreen Ijaz, Jacques Izopet, and Harry R. Dalton
Author affiliations: Author affiliations: Centre Hospitalier Universitaire Rangueil, Toulouse, France (N. Kamar, P. Cintas, L. Rostaing); Université Paul Sabatier, Toulouse (N. Kamar, J.M. Peron, L. Rostaing, J. Izopet); Royal Cornwall Hospital Trust, Truro, UK (R.P. Bendall, F. Keane, H.R. Dalton); Centre Hospitalier Universitaire Purpan, Toulouse (J.M. Peron, J.M. Mansuy, J. Izopet); Centre Hospitalier de Castres, Castres, France (L. Prudhomme); Health Protection Agency, London, UK (S. Ijaz); Peninsula College of Medicine and Dentistry, Truro (H.R. Dalton)

Main Article

Table 2

Clinical presentation for 7 patients with HEV–associated neurologic disorders, Cornwall, UK, and Toulouse, France*

Patient no. Neurologic signs and symptoms Therapy Outcome
1 Acute inflammatory polyradiculoneuropathy – Complete resolution
2 Bilateral brachial neuritis – Resolution with residual weakness
3 Guillain-Barré syndrome IV Ig Resolution at HEV clearance
4 Ataxia, severe proximal weakness of lower limbs, urine retention, and cognitive dysfunction IS modification Resolution with residual motor deficit
5 Encephalitis IS cessation, foscavir, IV Ig Complete resolution
6 Peripheral demyelinating polyradiculoneuropathy IS modification, IV Ig No improvement
7 Painful sensory peripheral neuropathy Peg-IFN/ribavirin Complete resolution

*HEV, hepatitis E virus; –, no specific therapy; IV Ig, intravenous immunoglobulins; IS, immunosuppressant, Peg-IFN, pegylated interferon.

Main Article

Page created: July 13, 2011
Page updated: July 13, 2011
Page reviewed: July 13, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external